Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced that data from its 1404 and PyLTM prostate cancer imaging programs will be presented at the upcoming Society of Nuclear Medicine and Molecular Imaging 2016 Annual Meeting, taking place from June 11 – 15, 2016 in San Diego, California.
Progenics Equity Analysis
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) opened trading today as $5.06 and is trading in the range of 4.53-5.09 today. Progenics current market cap stands at $353.93 Million.
Compared to other peers in the Biotechnology sector, Progenics has outperformed in terms of quarterly revenue growth year over year at 8.88 vs. the industry average of 0.18.
Progenics is currently covered by 4 Wall Street analysts. The mean target price is $10.75 according to First Call. This presents a solid upside to the current price of the equity. The Mean Recommendation sits at 1.3 which is based on 3 Strong Buy, 1 Buy ratings.
The most recent analyst actions consisted of Jefferies upgrading the stock on October 23th
The current quarter EPS consensus estimate is -0.13 with revenue estimates of 6.39M. Sales are expected to grow at a 229.90% rate. Progenics reported actual earnings last quarter of -0.18 which fails to beat the -0.13 consensus estimate, a -38.50% surprise.
Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. The companys primary clinical-stage product candidates include prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has completed Phase II testing in chemotherapy-experienced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma. It also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient; and for treatment of OIC inpatients with non-cancer pain. In addition, the company develops Relistor-oral that has completed Phase III testing for the treatment of OIC. Further, it develops MIP-1095, a PSMA-targeted small molecule radiopharmaceutical that is in clinical development stage for the treatment of prostate cancer. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA, as well as has collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.